Abbott Laboratories

Medical Devices • Healthcare • North Chicago, IL, United States • ABT (NYQ)

224 667 6100 100 Abbott Park Road, North Chicago, IL 60064-6400, United States

Quarter: Q4 2025 Reported: October 15, 2025 Sentiment: Neutral

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Analysis Summary

The provided earnings announcement for Abbott Laboratories' Q4 2025, which references Q3 2025 results, primarily focuses on the company's approach to non-GAAP financial reporting rather than specific financial outcomes. Consequently, there is no detailed revenue breakdown by segment, nor any specific revenue figures for the quarter. The announcement outlines various non-GAAP adjustments, including those related to acquisitions, restructuring actions, fair value adjustments to contingent consideration, certain regulatory costs, and the exclusion of intangible amortization expense. These adjustments are made to provide a clearer view of the underlying business performance, as internally assessed by management.

Without specific GAAP or non-GAAP financial metrics such as net income, gross margin, operating income, or earnings per share, it is impossible to assess Abbott's profitability or operational efficiency for Q4 2025 based on this announcement. The text explains that non-GAAP measures are used to adjust for "unusual or unpredictable" factors, aiming to give investors a better understanding of ongoing business performance. However, the absence of the actual adjusted or unadjusted financial results means that any analysis of the company's financial health, cost structure, or efficiency improvements cannot be conducted from this disclosure.

The announcement does not include any information regarding Abbott's strategic initiatives, recent business developments, or management commentary on market conditions, product pipelines, or competitive landscape. Its scope is strictly limited to the disclosure of the company's non-GAAP reporting practices and the timing of its Q3 2025 results. Therefore, insights into Abbott's corporate strategy, recent achievements, or future operational focus are entirely absent from this particular earnings release.

Crucially, the provided text contains no forward guidance for the upcoming quarter (Q1 2026) or the full fiscal year 2026. There are no projections for revenue, earnings, or any other key financial indicators. This absence of guidance, combined with the lack of current quarter performance data, prevents any assessment of Abbott's market positioning, future growth prospects, or management's outlook on the economic environment. Investors are left without the typical forward-looking statements that usually accompany earnings announcements.

Key Highlights

• Announcement of Q3 2025 results on October 15, 2025.
• Detailed explanation of non-GAAP financial measures and their purpose.
• Non-GAAP adjustments include acquisitions, restructuring, regulatory costs, and intangible amortization.
• Management uses non-GAAP metrics for internal performance assessment and investor clarity.
• Investors cautioned to consider non-GAAP in addition to GAAP measures.
• Absence of specific Q4 2025 financial results (revenue, net income, EPS).
• No forward-looking guidance provided for future periods.

Financial Metrics

eps

revenue

billion

guidance

net income

billion

Stock Performance (90 Days)

Data through Dec 30, 2025

Layoff Events

Earnings Calls

Positive Signals

• Transparency in detailing non-GAAP reporting methodology.
• Clear articulation of specific non-GAAP adjustments.
• Management's stated rationale for using non-GAAP measures.
• Adherence to regulatory disclosure requirements (Form 8-K filing).

Risks & Concerns

— Lack of specific Q4 2025 financial performance data in the announcement.
— Potential for investor confusion or misinterpretation due to absence of corresponding GAAP figures.
— Inability to assess current operational performance or future outlook based on this release.
— Reliance on non-GAAP measures for internal assessment may not fully capture GAAP financial realities.